Serial Passaging

The Mayo Clinic Brain Tumor Patient-Derived Xenograft National Resource has a specific methodology for serial passaging of patient-derived xenograft models as subcutaneous tumors.

Briefly, tumor tissue removed from an established xenograft is mechanically disaggregated in DMEM media, triturated through a 1-milliliter syringe, mixed with reduced growth factor Matrigel in a 1:1 ratio. Up to 200 microliters of this mixture is then injected subcutaneously in the flank of nude mice.

Files available: